Why the study?
Secondary tricuspid regurgitation is frequent, associated with excess mortality across HF subtypes, and rarely treated surgically or percutaneously, presenting a major projected healthcare burden.
Highlights the epidemiological burden and undertreatment of secondary tricuspid regurgitation in heart failure, suggesting a potential role for low-risk transcatheter therapies.
Secondary tricuspid regurgitation is frequent, increasing with age and associated with excess mortality independent of HF subtype. Nevertheless, sTR is rarely treated surgically or percutaneously. With the projected increase in HF prevalence and population ageing, the data suggest a major burden for healthcare systems that needs to be adequately addressed. Low-risk transcatheter treatment options may provide a suitable alternative.
No takes yet. Share an insight, caveat, or question.
Heitzinger et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: